Want to see IN:RPGLIFE full AI Analyst Report?
RPGLIFE Stock Chart & Stats
₹2303.55
-₹26.05(-1.12%)
At close: 4:00 PM EST
₹2303.55
-₹26.05(-1.12%)
Day’s Range― - ―
52-Week Range₹1,731.25 - ₹3,009.60
Previous CloseN/A
Volume11.08K
Average Volume (3M)3.23K
Market Cap
₹47.06B
Enterprise Value₹36.36B
Total Cash (Recent Filing)₹2.75B
Total Debt (Recent Filing)₹200.00M
Price to Earnings (P/E)41.1
Beta0.79
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.85%
Share Statistics
EPS (TTM)69.64
Shares Outstanding16,539,015
10 Day Avg. Volume8,652
30 Day Avg. Volume3,228
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)5.08
Price to Sales (P/S)4.34
P/FCF Ratio-38.40K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a conservatively positioned balance sheet provide durable financial flexibility. This supports sustained investment in branded formulations, allows the firm to withstand demand shocks, pursue selective M&A or capex, and reduces refinancing risk over the next 2–6 months.
Consistent Revenue GrowthMulti-year, mid-to-high single-digit revenue growth indicates resilient product demand and stable market position in prescription-led segments. Steady top-line expansion from repeat prescriptions supports predictable cash flows and long-term commercial scalability in domestic markets.
Historically Positive Operating Cash FlowConsistently positive operating cash flow historically demonstrates core cash-generating ability from operations. It underpins working-capital needs, funds routine capex and product investment, and provides a buffer for cyclical pressures despite the latest year’s temporary deterioration.
Bears Say
Margin Compression & VolatilityRecent, sharp margin decline and historical volatility weaken durable earnings power. If cost pressures or pricing challenges persist, operating and net margins may remain depressed, reducing free cash flow potential and making medium-term profit forecasts less reliable.
Weakened Cash Conversion / Negative FCFA decline in cash conversion and a shift to slightly negative free cash flow constrain financial flexibility. Sustained negative FCF would force reliance on external funding or cutbacks to capex/dividends, limiting strategic options and heightening vulnerability to working-capital swings.
Significant EPS DeclineA roughly 37% year-over-year EPS contraction signals meaningful stress on profitability beyond normal cyclicality. Such a marked decline can reflect structural margin, pricing, or cost issues that reduce reinvestment capacity and increase execution risk for near-term growth initiatives.
RPG Life Sciences Limited News
RPGLIFE FAQ
What was RPG Life Sciences Limited’s price range in the past 12 months?
RPG Life Sciences Limited lowest stock price was ₹1731.25 and its highest was ₹3009.60 in the past 12 months.
What is RPG Life Sciences Limited’s market cap?
RPG Life Sciences Limited’s market cap is ₹47.06B.
When is RPG Life Sciences Limited’s upcoming earnings report date?
RPG Life Sciences Limited’s upcoming earnings report date is Jul 24, 2026 which is in 4 days.
How were RPG Life Sciences Limited’s earnings last quarter?
RPG Life Sciences Limited released its earnings results on Apr 29, 2026. The company reported ₹18.078 earnings per share for the quarter, beating the consensus estimate of N/A by ₹18.078.
Is RPG Life Sciences Limited overvalued?
According to Wall Street analysts RPG Life Sciences Limited’s price is currently Overvalued.
Does RPG Life Sciences Limited pay dividends?
RPG Life Sciences Limited pays a Notavailable dividend of ₹24 which represents an annual dividend yield of 0.85%. See more information on RPG Life Sciences Limited dividends here
What is RPG Life Sciences Limited’s EPS estimate?
RPG Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RPG Life Sciences Limited have?
RPG Life Sciences Limited has 16,539,015 shares outstanding.
What happened to RPG Life Sciences Limited’s price movement after its last earnings report?
RPG Life Sciences Limited reported an EPS of ₹18.078 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.761%.
Which hedge fund is a major shareholder of RPG Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:RPGLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RPG Life Sciences Limited
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs) for both the Indian and global markets. The company provides synthetic APIs for diverse medical applications, including immunosuppression, psychiatric conditions, cardiac health (anti-anginals), parasitic infections (anthelmentics), seizure management (anticonvulsants), and muscle spasm relief (antispasmodics). While its generics portfolio primarily centers on immunosuppressant treatments, its finished dosage formulations address a wide spectrum of therapeutic areas, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular health, diabetology, orthopedics, neuropsychiatry, and respiratory conditions, among many others. Established in 1968 with its headquarters in Mumbai, India, the company adopted its current name in February 2008, having previously been known as RPG Pharmaceuticals Limited. RPG Life Sciences Limited functions as a subsidiary of Nucleus Life Trust.
Technical Analysis
Bliss Gvs Pharma Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―